HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes.

Abstract
Induction of HIV expression through lymphocyte activation has been proposed as a strategy to purge latent reservoirs. Prostratin is a non-tumourogenic phorbol ester that delays HIV replication in vitro, but paradoxically activates HIV expression in latently infected cells. To get a better insight into the mechanisms of action of prostratin, we have analysed the effect of prostratin on HIV activation and HIV receptor and coreceptors' surface expression in human lymphocytes. Peripheral blood mononuclear cells (PBMCs) were transfected with luciferase expression constructs under the control of wild type HIV-long terminal repeat (LTR) and consensus sequences for transcription factors involved in HIV-LTR transactivation (NF-kappaB, SP1, NFAT). Prostratin stimulates transactivation of LTR vectors, kappaB- and SP-1-driven luciferase constructs. In another set of experiments, PBMCs were transfected with a full-length infectious viral clone. Prostratin induced HIV transcription and viral expression as detected by luciferase activity in cellular extracts and p24 levels in culture supernatants, respectively. Expression of the HIV coreceptors CCR5 and CXCR4 was decreased by prostratin and, concomitantly, prostratin inhibited the infection of PBMCs with R5 and X4 strains. However, prostratin did not inhibit infection with a pseudotyped viral clone that enters into the cells independently of HIV receptors. These results help to explain the paradoxical effects of prostratin. On one hand, prostratin induces HIV activation in latently infected cells through the induction of NF-kappaB and Sp1. On the other hand, strong and persistent downregulation of HIV receptors decreases infection of new targets and delays HIV propagation. These data support the potential use of prostratin to activate HIV from latency and purge viral reservoirs.
AuthorsJoaquín Rullas, Mercedes Bermejo, Javier García-Pérez, Manuela Beltán, Nuria González, Marjan Hezareh, Stephen J Brown, José Alcamí
JournalAntiviral therapy (Antivir Ther) Vol. 9 Issue 4 Pg. 545-54 (Aug 2004) ISSN: 1359-6535 [Print] England
PMID15456086 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • NF-kappa B
  • Phorbol Esters
  • Receptors, CCR5
  • Receptors, CXCR4
  • Receptors, HIV
  • prostratin
Topics
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Down-Regulation
  • HIV (drug effects, genetics, physiology)
  • HIV Long Terminal Repeat
  • Humans
  • Leukocytes, Mononuclear (drug effects, metabolism, virology)
  • NF-kappa B (metabolism)
  • Phorbol Esters (pharmacology)
  • Receptors, CCR5 (metabolism)
  • Receptors, CXCR4 (metabolism)
  • Receptors, HIV (drug effects, metabolism)
  • Time Factors
  • Transcriptional Activation
  • Transfection
  • Virus Activation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: